Tests RSS0393 ointment for plaque psoriasis in children and teens
Tests RSS0393 ointment for skin plaques of psoriasis in children and adolescents.
Plain-language title generated from the registry record
Registry title: A Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 17 years old?
Source: NCT07102888, who can take part
Where in China
- Beijing Children's Hospital, Capital Medical UniversityBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jiangsu HengRui Medicine Co., Ltd.
- Trial code
- NCT07102888
- Record updated
- 5 August 2025
- Original description
This study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of RSS0393 topical ointment in the treatment of plaque psoriasis in children and adolescents.Read full original descriptionShow less
A Phase II Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis
This study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of RSS0393 topical ointment in the treatment of plaque psoriasis in children and adolescents.
Inclusion: Age ≥ 6 years old and < 18 years old at screening; History of plaque psoriasis ≥ 3 months; The subjects and their parents or legal guardians voluntarily signed informed consent before any study-related procedures began.
Exclusion: Subjects who have received topical medication for psoriasis within 14 days before baseline, or systemic medication or phototherapy for psoriasis within 28 days before baseline, or biological agents for psoriasis within a specified time before baseline; Subjects have other skin diseases or conditions that may affect the evaluation of the relevant endpoints of this study; Subjects with any other persistent active autoimmune disease; Diagnosis of psoriasis other than plaque at screening.